Garetosmab

( DrugBank: Garetosmab / KEGG DRUG: Garetosmab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
272	進行性骨化性線維異形成症	2

272. 進行性骨化性線維異形成症

臨床試験数 : 39 / 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05394116 (ClinicalTrials.gov)	November 21, 2022	4/5/2022	The Examination of Safety and Efficacy of GaretosmabVersus Placebo Administered Intravenously (IV) i ...	Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetos ...	Fibrodysplasia Ossificans Progressiva	Drug: Garetosmab;Drug: Placebo	Regeneron Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	66	Phase 3	Japan;Poland;Spain;United Kingdom
2	NCT04577820 (ClinicalTrials.gov)	October 13, 2021	30/9/2020	Study to Assess the Efficacy and Safety of Garetosmabin Japanese Adult Patients With Fibrodysplasia ...	Evaluation of Efficacy and Safety of Garetosmabin Japanese Adult Patients With Fibrodysplasia Ossifi ...	Fibrodyplasia Ossificans Progressiva (FOP);Heterotopic Ossification (HO)	Drug: garetosmab	Regeneron Pharmaceuticals	NULL	Withdrawn	18 Years	60 Years	All	0	Phase 3	NULL

First Previous1Next Last